GlassScriptPhysician profile
Elizabeth Mckenna
NPI 1861480584
$2,199.63
in general payments reported to CMS, 2019-2025
24 companies · $55.80 in 2025
The $55.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $199 · 2021: $356 · 2022: $420 · 2023: $633 · 2024: $289 · 2025: $55.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.79 | 2021-2025 | |
| Novo Nordisk INC | $337.56 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $226.05 | 2019-2024 | |
| Glaxosmithkline, LLC. | $193.66 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $170.61 | 2019-2024 | Airsupra, Breztri |
| Amgen INC. | $132.76 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $113.32 | 2020-2024 | Mounjaro |
| Abbott Laboratories | $100.00 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $99.72 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $60.02 | 2022-2024 | Injectafer |
| Almatica Pharma LLC | $50.36 | 2021-2022 | |
| Astellas Pharma US INC | $47.61 | 2022-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $42.12 | 2019 | |
| Merck Sharp & Dohme LLC | $39.49 | 2022-2023 | Gardasil 9, Vaxelis, Proquad |
| Esperion Therapeutics, INC. | $30.25 | 2021-2023 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2021-2024 | Eliquis |
| Allergan, INC. | $25.94 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.23 | 2022 | |
| Hologic Sales and Service, LLC | $18.27 | 2023 | Aptima |
| Alexion Pharmaceuticals, INC. | $17.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $16.26 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $15.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mckenna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.